| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802633701051 | 263370105 | LYRINEL PR.TAB 5MG/TAB BOTTLE x 30 TAB | 10.66 | 11.18 | 15.40 |
| 05/2018 | 2802633702058 | 263370205 | LYRINEL PR.TAB 10MG/TAB BOTTLE x 30 TAB | 20.14 | 21.13 | 29.12 |
| 05/2018 | 2802633703055 | 263370305 | LYRINEL PR.TAB 15MG/TAB BOTTLE x 30 ΤΑΒ | 21.15 | 22.19 | 30.59 |
For the treatment of overactive bladder.
Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.
LD<sub>50</sub>=1220 mg/kg (Orally in rats, Goldenthal)
Rapidly absorbed from gastrointestinal tract.
12.4-13.2 hours
Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
* 193 L